

Juan R Sanchez-Ramos

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4019759/juan-r-sanchez-ramos-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138
papers

10,961
citations

45
h-index

104
g-index

146
ext. papers

11,824
ext. citations

4.9
avg, IF

5.6
L-index

#	Paper	IF	Citations
138	Granulocyte Colony-Stimulating Factor Enhances Brain Repair Following Traumatic Brain Injury Without Requiring Activation of Cannabinoid Receptors. <i>Cannabis and Cannabinoid Research</i> , 2021 , 6, 48-57	4.6	0
137	The rise and fall of tobacco as a botanical medicine. <i>Journal of Herbal Medicine</i> , 2020 , 22, 100374	2.3	6
136	Data on enrichment of chitosan nanoparticles for intranasal delivery of oligonucleotides to the brain. <i>Data in Brief</i> , 2020 , 28, 105093	1.2	2
135	Awareness of Chorea in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2020 , 9, 99-103	1.9	2
134	Enriched chitosan nanoparticles loaded with siRNA are effective in lowering Huntington's disease gene expression following intranasal administration. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020 , 24, 102119	6	23
133	Method for Stimulation of Hippocampal Neurogenesis by Transient Microneedle Insertion. <i>Methods in Molecular Biology</i> , 2019 , 1919, 227-235	1.4	2
132	Optimizing Nanoparticle Design for Gene Therapy: Protection of Oligonucleotides from Degradation Without Impeding Release of Cargo 2018 , 2,		3
131	Chitosan-Mangafodipir nanoparticles designed for intranasal delivery of siRNA and DNA to brain. <i>Journal of Drug Delivery Science and Technology</i> , 2018 , 43, 453-460	4.5	24
130	The Parkinson's Active Living (PAL) Program. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017 , 30, 11-258		19
129	Self-reported impulsivity in Huntington's disease patients and relationship to executive dysfunction and reward responsiveness. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2017 , 39, 694-706	2.1	9
128	A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. <i>Neurology</i> , 2017 , 88, 152-159	6.5	75
127	Effects of an Inhibitor of Monocyte Recruitment on Recovery from Traumatic Brain Injury in Mice Treated with Granulocyte Colony-Stimulating Factor. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	5
126	Hippocampal Neurogenesis 2016 , 821-831		6
125	Transient Microneedle Insertion into Hippocampus Triggers Neurogenesis and Decreases Amyloid Burden in a Mouse Model of Alzheimer's Disease. <i>Cell Transplantation</i> , 2016 , 25, 1853-1861	4	1
124	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. <i>JAMA Neurology</i> , 2016 , 73, 102-10	17.2	29
123	Granulocyte colony-stimulating factor promotes behavioral recovery in a mouse model of traumatic brain injury. <i>Journal of Neuroscience Research</i> , 2016 , 94, 409-23	4.4	20
122	Magnetic resonance signal processing tool for diagnostic classification 2016 ,		3

121	Granulocyte-colony stimulating factor promotes brain repair following traumatic brain injury by recruitment of microglia and increasing neurotrophic factor expression. <i>Restorative Neurology and Neuroscience</i> , 2016 , 34, 415-31	2.8	14
120	Evaluation of an β synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 922-30	4.4	24
119	Cannabinoids for the Treatment of Movement Disorders. <i>Current Treatment Options in Neurology</i> , 2015 , 17, 370	4.4	5
118	Neurologic Complications of Psychomotor Stimulant Abuse. <i>International Review of Neurobiology</i> , 2015 , 120, 131-60	4.4	18
117	The entourage effect of the phytocannabinoids. <i>Annals of Neurology</i> , 2015 , 77, 1083	9.4	16
116	Examining Huntington's disease patient and informant concordance on frontally mediated behaviors. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015 , 37, 981-7	2.1	8
115	Combination therapy of human umbilical cord blood cells and granulocyte colony stimulating factor reduces histopathological and motor impairments in an experimental model of chronic traumatic brain injury. <i>PLoS ONE</i> , 2014 , 9, e90953	3.7	78
114	In vivo administration of granulocyte colony-stimulating factor restores long-term depression in hippocampal slices prepared from transgenic APP/PS1 mice. <i>Journal of Neuroscience Research</i> , 2014 , 92, 975-80	4.4	11
113	Medical marijuana in neurology. <i>Expert Review of Neurotherapeutics</i> , 2014 , 14, 1453-65	4.3	30
112	Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. <i>Experimental Brain Research</i> , 2013 , 228, 481-91	2.3	108
111	Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington's disease. <i>Stereotactic and Functional Neurosurgery</i> , 2013 , 91, 129-33	1.6	26
110	Hippocampal neurogenesis and the brain repair response to brief stereotaxic insertion of a microneedle. <i>Stem Cells International</i> , 2013 , 2013, 205878	5	12
109	Neon neurons. <i>Neurology</i> , 2013 , 80, 1815	6.5	
108	Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation. <i>Molecular Pharmaceutics</i> , 2012 , 9, 2094-102	5.6	89
107	Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2012 , 31, 843-55	4.3	31
106	Granulocyte-colony stimulating factor (G-CSF) enhances recovery in mouse model of Parkinson's disease. <i>Neuroscience Letters</i> , 2011 , 487, 153-7	3.3	14
105	Quantitative analysis of tremors in welders. <i>International Journal of Environmental Research and Public Health</i> , 2011 , 8, 1478-90	4.6	4
104	Hyperkinetic movement disorders associated with HIV and other viral infections. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2011 , 100, 323-34	3	14

103	Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. <i>International Journal of Neuroscience</i> , 2011 , 121, 472-6	2	5
102	GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 507-18	4.3	85
101	Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 191-210	4.3	148
100	Vitamin A metabolite, all-trans-retinoic acid, mediates alternative splicing of protein kinase C deltaVIII (PKCdeltaVIII) isoform via splicing factor SC35. <i>Journal of Biological Chemistry</i> , 2010 , 285, 25987-95	5.4	26
99	Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine. <i>Crystal Growth and Design</i> , 2010 , 10, 394-405	3.5	194
98	A randomized, placebo-controlled trial of latrepirdine in Huntington disease. <i>Archives of Neurology</i> , 2010 , 67, 154-60		73
97	The independent influence of apathy and depression on cognitive functioning in Parkinson's disease. <i>Neuropsychology</i> , 2010 , 24, 721-30	3.8	62
96	Effects of MDMA ("ecstasy") during adolescence on place conditioning and hippocampal neurogenesis. <i>European Journal of Pharmacology</i> , 2010 , 628, 96-103	5.3	22
95	A futility study of minocycline in Huntington's disease. <i>Movement Disorders</i> , 2010 , 25, 2219-24	7	67
94	Well-being of family caregivers of persons with late-stage Huntington's disease: lessons in stress and coping. <i>Health Communication</i> , 2009 , 24, 239-48	3.2	26
93	Effects of environmental enrichment and physical activity on neurogenesis in transgenic PS1/APP mice. <i>Brain Research</i> , 2009 , 1256, 173-9	3.7	34
92	Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. <i>Neuroscience</i> , 2009 , 163, 55-72	3.9	120
91	Hematopoietic growth factors: Novel therapeutic strategy for Alzheimer's disease. <i>Drugs of the Future</i> , 2009 , 34, 977	2.3	2
90	The potential of hematopoietic growth factors for treatment of Alzheimer's disease: a mini-review. <i>BMC Neuroscience</i> , 2008 , 9 Suppl 2, S3	3.2	16
89	Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. <i>Archives of Neurology</i> , 2008 , 65, 1582-9		61
88	Preparation of neural progenitors from bone marrow and umbilical cord blood. <i>Methods in Molecular Biology</i> , 2008 , 438, 123-34	1.4	15
87	Dieldrin elicits a widespread DNA repair and antioxidative response in mouse brain. <i>Journal of Biochemical and Molecular Toxicology</i> , 2007 , 21, 125-35	3.4	11
86	A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. <i>Movement Disorders</i> , 2007 , 22, 279-82	7	74

85	Long-term cultured human umbilical cord neural-like cells transplanted into the striatum of NOD SCID mice. <i>Brain Research Bulletin</i> , 2007 , 74, 155-63	3.9	29
84	Comparison of neuron-like cells derived from bone marrow stem cells to those differentiated from adult brain neural stem cells. <i>Stem Cells and Development</i> , 2007 , 16, 747-56	4.4	42
83	Adult hippocampal neural stem/progenitor cells in vitro are vulnerable to the mycotoxin ochratoxin-A. <i>Toxicological Sciences</i> , 2007 , 98, 187-97	4.4	42
82	Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. <i>Movement Disorders</i> , 2006 , 21, 1998-2001	7	24
81	Primary malignant tumors of the heart: four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells. <i>Cardiology</i> , 2006 , 105, 226-33	1.6	9
80	Stem cells from umbilical cord blood. <i>Seminars in Reproductive Medicine</i> , 2006 , 24, 358-69	1.4	15
79	Can low level exposure to ochratoxin-A cause parkinsonism?. <i>Journal of the Neurological Sciences</i> , 2006 , 249, 68-75	3.2	41
78	Acute neurotoxic effects of the fungal metabolite ochratoxin-A. <i>NeuroToxicology</i> , 2006 , 27, 82-92	4.4	103
77	Neuroanatomical mapping of DNA repair and antioxidative responses in mouse brain: Effects of a single dose of MPTP. <i>NeuroToxicology</i> , 2006 , 27, 1080-93	4.4	10
76	Transcriptional profile of NeuroD expression in a human fetal astroglial cell line. <i>Gene Expression</i> , 2005 , 12, 123-36	3.4	4
75	Levetiracetam-induced parkinsonism in a Huntington disease patient. <i>Clinical Neuropharmacology</i> , 2005 , 28, 188-90	1.4	15
74	Human umbilical cord blood progenitors: the potential of these hematopoietic cells to become neural. <i>Stem Cells</i> , 2005 , 23, 1560-70	5.8	106
73	Four peptide hormones decrease the number of human breast adenocarcinoma cells. <i>European Journal of Clinical Investigation</i> , 2005 , 35, 60-9	4.6	36
72	Five cardiac hormones decrease the number of human small-cell lung cancer cells. <i>European Journal of Clinical Investigation</i> , 2005 , 35, 388-98	4.6	37
71	Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. <i>European Journal of Clinical Investigation</i> , 2005 , 35, 700-10	4.6	25
70	Effects of melanin and manganese on DNA damage and repair in PC12-derived neurons. <i>Free Radical Biology and Medicine</i> , 2004 , 36, 1144-54	7.8	18
69	Do hematopoietic cells exposed to a neurogenic environment mimic properties of endogenous neural precursors?. <i>Journal of Neuroscience Research</i> , 2004 , 76, 244-54	4.4	44
68	Green fluorescent protein bone marrow cells express hematopoietic and neural antigens in culture and migrate within the neonatal rat brain. <i>Journal of Neuroscience Research</i> , 2004 , 76, 255-64	4.4	14

67	Expression of brain natriuretic peptide by human bone marrow stromal cells. <i>Experimental Neurology</i> , 2004 , 185, 191-7	5-7	65
66	Rubratoin B elicits antioxidative and DNA repair responses in mouse brain. <i>Gene Expression</i> , 2004 , 11, 211-9	3-4	3
65	Mobilized peripheral blood cells administered intravenously produce functional recovery in stroke. <i>Cell Transplantation</i> , 2003 , 12, 449-54	4	103
64	Strain-specific differences in the expression and activity of Ogg1 in the CNS. <i>Gene Expression</i> , 2003 , 11, 47-53	3-4	6
63	Intravenous versus intrastriatal cord blood administration in a rodent model of stroke. <i>Journal of Neuroscience Research</i> , 2003 , 73, 296-307	4-4	263
62	Brain as the Sea of Marrow. <i>Experimental Neurology</i> , 2003 , 184, 54-60	5-7	20
61	Human Umbilical Cord Blood Cells Express Neural Antigens after Transplantation into the Developing Rat Brain. <i>Cell Transplantation</i> , 2002 , 11, 265-274	4	126
60	Intravenous Administration of Human Umbilical Cord Blood Reduces Neurological Deficit in the Rat after Traumatic Brain Injury. <i>Cell Transplantation</i> , 2002 , 11, 275-281	4	228
59	Effects of diethylmaleate on DNA damage and repair in the mouse brain. <i>Free Radical Biology and Medicine</i> , 2002 , 33, 292-8	7-8	19
58	Neural cells derived from adult bone marrow and umbilical cord blood. <i>Journal of Neuroscience Research</i> , 2002 , 69, 880-93	4-4	256
57	The straight dope on addiction to dopamimetic drugs. <i>Movement Disorders</i> , 2002 , 17, 223-5	7	11
56	Chronic Cannabis Use in the Compassionate Investigational New Drug Program. <i>Journal of Cannabis Therapeutics</i> , 2002 , 2, 3-57		32
55	Physiological assessment of paroxysmal dystonia secondary to subacute sclerosing panencephalitis 2002 , 17, 154		1
54	Human umbilical cord blood cells express neural antigens after transplantation into the developing rat brain. <i>Cell Transplantation</i> , 2002 , 11, 265-74	4	29
53	Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury. <i>Cell Transplantation</i> , 2002 , 11, 275-81	4	73
52	Apoptosis in cultured hNT neurons. <i>Developmental Brain Research</i> , 2001 , 127, 63-70		7
51	Comparison of base-excision repair capacity in proliferating and differentiated PC 12 cells following acute challenge with dieldrin. <i>Free Radical Biology and Medicine</i> , 2001 , 31, 1272-8	7-8	20
50	Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. <i>Stroke</i> , 2001 , 32, 2682-8	6-7	1001

49	Expression of neural markers in human umbilical cord blood. <i>Experimental Neurology</i> , 2001 , 171, 109-15	5.7	171
48	The X-gal caution in neural transplantation studies. <i>Cell Transplantation</i> , 2000 , 9, 657-67	4	47
47	DNA damage, repair, and antioxidant systems in brain regions: a correlative study. <i>Free Radical Biology and Medicine</i> , 2000 , 28, 779-85	7.8	98
46	Adult bone marrow stromal cells differentiate into neural cells in vitro. <i>Experimental Neurology</i> , 2000 , 164, 247-56	5.7	1189
45	Relationship of Organochlorine Pesticides to Parkinsonism 2000 , 237-245		1
44	Sympathetic skin response and heart rate variability in patients with Huntington disease. <i>Archives of Neurology</i> , 1999 , 56, 1248-52		48
43	Oxidative DNA damage in the aging mouse brain. <i>Movement Disorders</i> , 1999 , 14, 972-80	7	90
42	Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependence. <i>Annals of the New York Academy of Sciences</i> , 1998 , 844, 274-292	6.5	87
41	Mortality in DATATOP: a multicenter trial in early Parkinson disease. Parkinson Study Group. <i>Annals of Neurology</i> , 1998 , 43, 318-25	9.4	152
40	Attenuation of age-dependent oxidative damage to DNA and protein in brainstem of Tg Cu/Zn SOD mice. <i>Neurobiology of Aging</i> , 1998 , 19, 311-6	5.6	37
39	Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures. <i>Experimental Neurology</i> , 1998 , 150, 263-71	5.7	80
38	Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. <i>Archives of Neurology</i> , 1998 , 55, 1211-6		81
37	Transgenic murine dopaminergic neurons expressing human Cu/Zn superoxide dismutase exhibit increased density in culture, but no resistance to methylphenylpyridinium-induced degeneration. <i>Journal of Neurochemistry</i> , 1997 , 68, 58-67	6	14
36	Unified Huntington Disease Rating Scale: reliability and consistency. Huntington Study Group. <i>Movement Disorders</i> , 1996 , 11, 136-42	7	1626
35	High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. <i>Movement Disorders</i> , 1996 , 11, 327-9	7	58
34	Reversible parkinsonian syndrome complicating cysticercus midbrain encephalitis. <i>Movement Disorders</i> , 1995 , 10, 215-9	7	21
33	Gait abnormality in essential tremor. <i>Movement Disorders</i> , 1994 , 9, 193-6	7	149
32	Parkinson disease and brain levels of organochlorine pesticides. <i>Annals of Neurology</i> , 1994 , 36, 100-3	9.4	269

31	Psychostimulants. <i>Neurologic Clinics</i> , 1993 , 11, 535-554	4.5	11
30	Trinucleotide repeat length instability and age of onset in Huntington@ disease. <i>Nature Genetics</i> , 1993 , 4, 387-92	36.3	875
29	Autonomic dysfunction in men with Parkinson@ disease. <i>European Neurology</i> , 1992 , 32, 134-40	2.1	115
28	Analysis of the protective effects of 21-aminosteroids in MPP(+)-induced neurotoxicity to dopaminergic neurons in mesencephalic cultures. <i>Annals of the New York Academy of Sciences</i> , 1992 , 648, 338-9	6.5	
27	21-aminosteroids interact with the dopamine transporter to protect against 1-methyl-4-phenylpyridinium-induced neurotoxicity. <i>Journal of Neurochemistry</i> , 1992 , 58, 328-34	6	18
26	Banisterine and Parkinson@ disease. <i>Clinical Neuropharmacology</i> , 1991 , 14, 391-402	1.4	31
25	Selective and nonselective effects of 1-methyl-4-phenylpyridinium on oxygen consumption in rat striatal and hippocampal slices. <i>Journal of Neurochemistry</i> , 1991 , 57, 1340-6	6	13
24	Distribution and number of transferrin receptors in Parkinson@ disease and in MPTP-treated mice. <i>Experimental Neurology</i> , 1991 , 114, 73-81	5.7	42
23	Levodopa-responsive parkinsonism in a patient with Down@ syndrome. <i>European Neurology</i> , 1990 , 30, 247-8	2.1	6
22	Toxicity of 1-methyl-4-phenylpyridinium for rat dopaminergic neurons in culture: selectivity and irreversibility. <i>Journal of Neurochemistry</i> , 1990 , 54, 1102-9	6	73
21	Huntington@ disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. <i>Movement Disorders</i> , 1990 , 5, 93-9	7	192
20	Sleep disorders and sleep effect in Parkinson@ disease. <i>Movement Disorders</i> , 1990 , 5, 280-5	7	298
19	The role of mitochondrial DNA in Huntington@ disease. <i>Journal of Molecular Neuroscience</i> , 1989 , 1, 129-36	3	3
18	The role of mitochondrial DNA in Huntington@ disease. <i>Journal of Molecular Neuroscience</i> , 1989 , 1, 129-36	9	9
17	Trauma as an etiologic agent in Parkinson disease. <i>Movement Disorders</i> , 1989 , 4, 90-2	7	6
16	Hemichorea-hemiballismus associated with acquired immune deficiency syndrome and cerebral toxoplasmosis. <i>Movement Disorders</i> , 1989 , 4, 266-73	7	34
15	Trauma as an etiology of parkinsonism: opinions in the nineteenth century. <i>Movement Disorders</i> , 1989 , 4, 283-5	7	5
14	A case of post-traumatic tic disorder. <i>Movement Disorders</i> , 1989 , 4, 342-4	7	34

13	MPP ⁺ -induced pathophysiology demonstrates advantages of neurotoxicology studies in brain slices. <i>Journal of Neuroscience Methods</i> , 1989 , 28, 51-7	3	6
12	Cocaine and Tourette's syndrome. <i>Annals of Neurology</i> , 1988 , 23, 423-4	9.4	19
11	Trauma as an etiology of parkinsonism: a historical review of the concept. <i>Movement Disorders</i> , 1988 , 3, 30-6	7	72
10	Delayed-onset dystonia associated with corticospinal tract dysfunction. <i>Movement Disorders</i> , 1988 , 3, 201-10	7	36
9	Selective destruction of cultured dopaminergic neurons from fetal rat mesencephalon by 1-methyl-4-phenylpyridinium: cytochemical and morphological evidence. <i>Journal of Neurochemistry</i> , 1988 , 50, 1934-44	6	83
8	MPP ⁺ -induced increases in extracellular potassium ion activity in rat striatal slices suggest that consequences of MPP ⁺ neurotoxicity are spread beyond dopaminergic terminals. <i>Brain Research</i> , 1988 , 475, 283-90	3.7	14
7	1-Methyl-4-phenylpyridinium (MPP ⁺) increases oxidation of cytochrome-b in rat striatal slices. <i>Brain Research</i> , 1988 , 443, 183-9	3.7	20
6	Toxicity of Structural Analogs of 1-methyl-4-Phenyl Pyridinium (MPP ⁺) and Related Compounds on Dopaminergic Neurons in Culture 1988 , 137-143		
5	Mechanisms of MPP ⁺ Neurotoxicity: Oxyradical and Mitochondrial Inhibition Hypotheses 1988 , 145-152		5
4	A double-blind evaluation of ciladopa in Parkinson's disease. <i>Movement Disorders</i> , 1987 , 2, 211-7	7	2
3	1-Methyl-4-phenylpyridinium (MPP ⁺) but not 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) selectively destroys dopaminergic neurons in cultures of dissociated rat mesencephalic neurons. <i>Neuroscience Letters</i> , 1986 , 72, 215-20	3.3	72
2	An artifact of liquid emulsion autoradiography. <i>Biotechnic & Histochemistry</i> , 1978 , 53, 163-8		
1	Movement Disorders and Dopaminomimetic Stimulant Drugs 351-370		